🇺🇸 FDA
Pipeline program

ZN-d5 ZN-c3

ZN-d5-004C

Phase 2 small_molecule terminated

Quick answer

ZN-d5 ZN-c3 for Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at Zentalis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Zentalis Pharmaceuticals
Indication
Acute Myeloid Leukemia (AML)
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials